title: Current approaches to the management of hemochromatosis.
abstract: The term hemochromatosis encompasses at least four types of genetic iron overload conditions, most of them recently distinguished from one another as a result of the identification of a series of genes related to iron metabolism. At least three of these entities (HFE hemochromatosis, juvenile hemochromatosis and transferrin receptor 2 hemochromatosis) involve systemic hepcidin deficiency as a key pathogenetic factor. Major advances in the management of hemochromatosis influence the diagnostic approach to the disease, with the development of an overall non invasive strategy, mainly based on clinical, biological (iron parameters and genetic testing), and imaging (especially magnetic resonance imaging) data. Therapeutic management remains, on the curative side, dominated by phlebotomy (venesection), practical aspects of which have been recently revisited by the Guidelines Department of the French "Haute Autorité de Santé." However, innovative treatment approaches, based on the improved pathophysiological understanding of these diseases and the progress in iron chelation therapy, are emerging. Preventive therapy, focused on family screening, remains a key part of the management of hemochromatosis.
authors.affiliation: Service des Maladies du Foie, University Hospital Pontchaillou, Rennes, France. pierre.brissot@univ-rennes1.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Brissot
authors.forename: Frédéric
authors.initials: F
authors.lastname: de Bels
mesh_terms: D023181:Antimicrobial Cationic Peptides / Q000172:deficiency; D019468:Disease Management; D006432:Hemochromatosis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D064451:Hepcidins; D006801:Humans; D019190:Iron Overload / Q000235:genetics
chemical_list: D023181:Antimicrobial Cationic Peptides; C578702:HAMP protein, human; D064451:Hepcidins